Welwyn, United Kingdom

Brian Peter Slingsby

USPTO Granted Patents = 2 


Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Welwyn, GB (2009)
  • Harlow, GB (2009)

Company Filing History:


Years Active: 2009

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Brian Peter Slingsby: Pioneering Advances in Pain Treatment

Introduction

Brian Peter Slingsby, based in Welwyn, GB, is an accomplished inventor with a focus on developing innovative pharmaceutical solutions. He holds two patents, showcasing his dedication to advancing medical treatments specifically targeting pain and related disorders.

Latest Patents

Slingsby's most recent innovations include two notable patents. The first patent involves pyrimidine derivatives and their application as CB2 modulators. This invention is critical as it addresses the use of these novel compounds in pharmaceutical compositions aimed at treating diseases linked to the cannabinoid receptor's activity. His second patent features pyrrolopyridine derivatives, which, like the first, are designed for therapeutic compositions targeting pain management through modulation of the cannabinoid receptor function.

Career Highlights

Currently, Brian Peter Slingsby is part of Glaxo Group Limited, a leading company in the pharmaceutical industry. His contributions have paved the way for new treatments that may enhance patient care in pain management.

Collaborations

Throughout his career, Slingsby has collaborated with esteemed colleagues, including Andrew John Eatherton and Gerard Martin Paul Giblin. These partnerships have likely fostered a creative environment for developing groundbreaking solutions to pressing medical challenges.

Conclusion

Brian Peter Slingsby's work exemplifies the spirit of innovation within the pharmaceutical field. His patents in pyrimidine and pyrrolopyridine derivatives demonstrate a commitment to improving treatment outcomes for individuals suffering from pain, marking significant progress in the ongoing quest for effective medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…